Phase IV study to assess, the effect of hepatic impairment on the pharmacokinetics of Thiotepa and the potential of Thiotepa to alter the QT interval in pedatric patients undergoing allogeneic haematopoietic progenitor cell transplantation.
Phase of Trial: Phase IV
Latest Information Update: 30 Mar 2016
At a glance
- Drugs Thiotepa (Primary)
- Indications Haematological disorders
- Focus Pharmacokinetics
- Sponsors ADIENNE
- 26 Mar 2016 Status changed from recruiting to discontinued, according to European Clinical Trials Database record.
- 13 Mar 2015 Planned number of patients changed from 1 to 30.
- 11 Mar 2015 New trial record